AR102247A1 - Compuestos de carboxilato de fenilcetona y composiciones farmacéuticas para la prevención y tratamiento de osteoporosis - Google Patents

Compuestos de carboxilato de fenilcetona y composiciones farmacéuticas para la prevención y tratamiento de osteoporosis

Info

Publication number
AR102247A1
AR102247A1 ARP150103295A ARP150103295A AR102247A1 AR 102247 A1 AR102247 A1 AR 102247A1 AR P150103295 A ARP150103295 A AR P150103295A AR P150103295 A ARP150103295 A AR P150103295A AR 102247 A1 AR102247 A1 AR 102247A1
Authority
AR
Argentina
Prior art keywords
osteoporosis
prevention
treatment
mcooh
pharmaceutical compositions
Prior art date
Application number
ARP150103295A
Other languages
English (en)
Inventor
Grouix Brigitte
Gagnon Lyne
Original Assignee
Prometic Biosciences Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Prometic Biosciences Inc filed Critical Prometic Biosciences Inc
Publication of AR102247A1 publication Critical patent/AR102247A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/196—Carboxylic acids, e.g. valproic acid having an amino group the amino group being directly attached to a ring, e.g. anthranilic acid, mefenamic acid, diclofenac, chlorambucil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A61K31/222—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin with compounds having aromatic groups, e.g. dipivefrine, ibopamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/235—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids having an aromatic ring attached to a carboxyl group
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C59/00—Compounds having carboxyl groups bound to acyclic carbon atoms and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups
    • C07C59/40—Unsaturated compounds
    • C07C59/76—Unsaturated compounds containing keto groups
    • C07C59/84—Unsaturated compounds containing keto groups containing six membered aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C59/00—Compounds having carboxyl groups bound to acyclic carbon atoms and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups
    • C07C59/40—Unsaturated compounds
    • C07C59/76—Unsaturated compounds containing keto groups
    • C07C59/86—Unsaturated compounds containing keto groups containing six-membered aromatic rings and other rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C59/00—Compounds having carboxyl groups bound to acyclic carbon atoms and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups
    • C07C59/40—Unsaturated compounds
    • C07C59/76—Unsaturated compounds containing keto groups
    • C07C59/90—Unsaturated compounds containing keto groups containing singly bound oxygen-containing groups
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/275—Nitriles; Isonitriles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/662—Phosphorus acids or esters thereof having P—C bonds, e.g. foscarnet, trichlorfon
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Epidemiology (AREA)
  • Rheumatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Emergency Medicine (AREA)
  • Immunology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Reivindicación 1: Un método para la prevención y/o el tratamiento de la osteoporosis, que comprende la etapa de; administrarle a un sujeto que lo necesita un compuesto representado por la fórmula (1), o una sal farmacéuticamente aceptable de este, en donde: R¹ y R² son independientemente iguales a H, F o OH; A es (CH₂)ₘCOOH, W(CH₂)ₘCOOH o un resto de fórmula (2) cuando B es H; o B es (CH₂)ₘCOOH, W(CH₂)ₘCOOH o el resto de fórmula (2) cuando A es H; o A y B se unen covalentemente para formar un cicloalquilo de cinco (5), seis (6) o siete (7) miembros sustituido con COOH; en donde: Y es O, S, NH o CH₂; W es O, S o NH; m es 0 - 2; y p es 3 - 7; D es CO(CH₂)ₙCH₃ o CHOH(CH₂)ₙCH₃ o O(CH₂)ₙCH₃ donde n es 2 - 6; y E es H o F. Reivindicación 12: El método de cualquiera de las reivindicaciones de 1 a 11 caracterizado por que dicho compuesto se selecciona del grupo que consiste en los compuestos representados por las estructuras del grupo de fórmulas (3); y sales farmacéuticamente aceptables de estos.
ARP150103295A 2014-10-10 2015-10-13 Compuestos de carboxilato de fenilcetona y composiciones farmacéuticas para la prevención y tratamiento de osteoporosis AR102247A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201462062660P 2014-10-10 2014-10-10

Publications (1)

Publication Number Publication Date
AR102247A1 true AR102247A1 (es) 2017-02-15

Family

ID=55652426

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP150103295A AR102247A1 (es) 2014-10-10 2015-10-13 Compuestos de carboxilato de fenilcetona y composiciones farmacéuticas para la prevención y tratamiento de osteoporosis

Country Status (22)

Country Link
US (1) US10925846B2 (es)
EP (1) EP3204000B1 (es)
JP (1) JP6700638B2 (es)
KR (1) KR20170066613A (es)
CN (1) CN106999459B (es)
AR (1) AR102247A1 (es)
AU (1) AU2015330642B2 (es)
BR (1) BR112017007386A2 (es)
CA (1) CA2963358C (es)
DK (1) DK3204000T3 (es)
ES (1) ES2794782T3 (es)
IL (1) IL251409B (es)
MX (1) MX2017004735A (es)
MY (1) MY187511A (es)
PH (1) PH12017500636A1 (es)
PL (1) PL3204000T3 (es)
PT (1) PT3204000T (es)
RU (1) RU2712027C2 (es)
SG (1) SG11201702810TA (es)
TW (1) TWI723962B (es)
UY (1) UY36355A (es)
WO (1) WO2016054725A1 (es)

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006124662A1 (en) * 2005-05-13 2006-11-23 Synta Pharmaceuticals Corp. Il-12 modulatory compounds
EP2488208B1 (en) * 2009-10-14 2018-11-21 The Governors of the University of Alberta Compounds having peptides conjugated to bone targeting moieties and methods of making and using thereof
US9475750B2 (en) * 2010-10-27 2016-10-25 Prometic Biosciences Inc. Phenylketone carboxylate compounds and pharmaceutical uses thereof
WO2012097428A1 (en) * 2010-10-27 2012-07-26 Prometic Biosciences Inc. Compounds and pharmaceutical compositions for uses in diabetes
US9114118B2 (en) * 2010-10-27 2015-08-25 Prometic Biosciences Inc. Compounds and compositions for the treatment of cancer
WO2014138372A1 (en) * 2013-03-06 2014-09-12 Primavera Biosciences, Inc. Composition and method for treating osteoarthritis

Also Published As

Publication number Publication date
RU2712027C2 (ru) 2020-01-27
CA2963358A1 (en) 2016-04-14
CN106999459B (zh) 2020-07-10
DK3204000T3 (da) 2020-04-06
ES2794782T3 (es) 2020-11-19
IL251409A0 (en) 2017-05-29
TWI723962B (zh) 2021-04-11
WO2016054725A1 (en) 2016-04-14
SG11201702810TA (en) 2017-05-30
PT3204000T (pt) 2020-05-06
MY187511A (en) 2021-09-24
JP6700638B2 (ja) 2020-05-27
EP3204000B1 (en) 2020-01-08
BR112017007386A2 (pt) 2018-01-23
PH12017500636A1 (en) 2017-09-25
MX2017004735A (es) 2017-11-17
UY36355A (es) 2016-06-01
CN106999459A (zh) 2017-08-01
EP3204000A1 (en) 2017-08-16
US10925846B2 (en) 2021-02-23
US20190038580A1 (en) 2019-02-07
RU2017116154A3 (es) 2019-05-06
KR20170066613A (ko) 2017-06-14
AU2015330642B2 (en) 2019-07-04
CA2963358C (en) 2023-03-07
TW201618761A (zh) 2016-06-01
JP2017530179A (ja) 2017-10-12
EP3204000A4 (en) 2018-06-20
PL3204000T3 (pl) 2020-07-27
IL251409B (en) 2020-08-31
RU2017116154A (ru) 2018-11-12
AU2015330642A1 (en) 2017-05-11

Similar Documents

Publication Publication Date Title
ES2634490T3 (es) Derivados de ácido napht-2-ylacetico para tratar el sida
AR122783A2 (es) Inhibidores de kras g12c y métodos para su uso
CL2020000610A1 (es) Compuestos de bisamida que activan el sarcómero y sus usos.
EA201792259A1 (ru) Бензимидазольные и имидазопиридиновые карбоксимидамидные соединения
EA201791420A1 (ru) Соединения триазолопиримидина и их применения
AR094959A1 (es) Compuestos de imidazo piridina
NZ729037A (en) Carboxylic acid compound, method for preparation thereof, and use thereof
CL2019001041A1 (es) Compuestos terapéuticos y métodos para utilizarlos.
CY1124251T1 (el) Παραγωγα καρβοξαμιδιου
EA201792425A1 (ru) Трициклические соединения и их применение в качестве ингибиторов фосфодиэстераз
UY37941A (es) Derivados de bencimidazol y sus usos
AR105821A1 (es) COMPUESTOS ÚTILES PARA INHIBIR ROR-g-T
CY1124967T1 (el) Παραγωγα αμινοπυριδινης και χρηση αυτων ως εκλεκτικοι αναστολεις alk-2
TW201613603A (en) Pharmaceutical preparation
PE20181040A1 (es) Formulacion solida oral que contiene irinotecan y metodo de preparacion de la misma
UY36123A (es) Derivados de carboxamida
AR102246A1 (es) Compuestos aromáticos sustituidos y composiciones farmacéuticas para la prevención y tratamiento de osteoporosis, usos
CY1124838T1 (el) Αλας παραγωγου κεφαλοσπορινης, κρυσταλλικη, στερεη μορφη αυτου και μεθοδος παραγωγης αυτου
CY1123406T1 (el) Παραγωγο τριαζολοπυραζινονης χρησιμο ως ενας ανθρωπινος pde1 αναστολεας
EA201791396A1 (ru) ПРОИЗВОДНЫЕ ИМИДАЗОПИРИДАЗИНА В КАЧЕСТВЕ ИНГИБИТОРОВ PI3Kβ
CU20190042A7 (es) Compuestos derivados de naftiridinona
EA201791397A1 (ru) СВЯЗАННЫЕ С ГЕТЕРОЦИКЛИЛАМИ ПРОИЗВОДНЫЕ ИМИДАЗОПИРИДАЗИНА В КАЧЕСТВЕ ИНГИБИТОРОВ PI3Kβ
CY1119666T1 (el) Φαρμακευτικες συνθεσεις
EA201692090A1 (ru) Полициклические активаторы herg
AR102247A1 (es) Compuestos de carboxilato de fenilcetona y composiciones farmacéuticas para la prevención y tratamiento de osteoporosis

Legal Events

Date Code Title Description
FB Suspension of granting procedure